PMS-PIROXICAM SUPPOSITORIES-10MG SUPPOSITORY

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

PIROXICAM

Sẵn có từ:

PHARMASCIENCE INC

Mã ATC:

M01AC01

INN (Tên quốc tế):

PIROXICAM

Liều dùng:

10MG

Dạng dược phẩm:

SUPPOSITORY

Thành phần:

PIROXICAM 10MG

Tuyến hành chính:

RECTAL

Các đơn vị trong gói:

30 SUPPOSITORIES

Loại thuốc theo toa:

Prescription

Khu trị liệu:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0114612002; AHFS:

Tình trạng ủy quyền:

CANCELLED POST MARKET

Ngày ủy quyền:

2016-10-28

Đặc tính sản phẩm

PRODUCT MONOGRAPH
Pr
pms-PIROXICAM
Piroxicam, USP
10 mg and 20 mg Capsules
10 mg and 20 mg Suppositories
Nonsteroidal Anti-Inflammatory Drug (NSAID)
PHARMASCIENCE INC.
DATE OF REVISION:
6111 Royalmount Avenue
February 17, 2010
Montreal, Quebec
H4P 2T4
CONTROL # 131400
_ _
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..........................................................3
SUMMARY PRODUCT INFORMATION
.......................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS..................................................................................5
ADVERSE
REACTIONS..................................................................................................14
DRUG INTERACTIONS
.................................................................................................19
DOSAGE AND ADMINISTRATION
..............................................................................22
OVERDOSAGE
................................................................................................................23
ACTION AND CLINICAL
PHARMACOLOGY.............................................................23
STORAGE AND
STABILITY..........................................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................24
PART II: SCIENTIFIC INFORMATION
................................................................................26
PHARMACEUTICAL
INFORMATION..........................................................................26
CLINICAL TRIALS
..........................................................................................................27
DETAILED PHARMACOLOGY
.....................................................................................27